Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

Abstract Background. mTOR inhibitors are currently used in the treatment of solid malignancies. Since their approval, several cases of pulmonary toxicity (PT) have been described. This analysis aims to report the incidence and the risk of PT in published randomized controlled trials. Material and me...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta oncologica 2012-09, Vol.51 (7), p.873-879
Hauptverfasser:	Iacovelli, Roberto, Palazzo, Antonella, Mezi, Silvia, Morano, Federica, Naso, Giuseppe, Cortesi, Enrico
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Breast Neoplasms - drug therapy Carcinoma, Renal Cell - drug therapy Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Everolimus Humans Incidence Kidney Neoplasms - drug therapy Lung - drug effects Lung - physiopathology Neoplasms - drug therapy Neuroendocrine Tumors - drug therapy Pneumonia - chemically induced Randomized Controlled Trials as Topic Respiratory Function Tests Risk Sirolimus - administration & dosage Sirolimus - adverse effects Sirolimus - analogs & derivatives TOR Serine-Threonine Kinases - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!